Sensyne Health, Bayer collaborate on new AI-powered treatments for heart disease

Sensyne Health, a British artificial intelligence technology company, has signed an initial two-year collaboration agreement with Bayer to accelerate the clinical development of new treatments for cardiovascular disease using Sensyne Health's proprietary clinical AI technology platform. The initial agreement will generate revenue for Sensyne Health of £5 million across the two-year collaboration. Sensyne Health's partner National Health Service trusts will receive a 4% share of all revenue generated by Sensyne Health under this collaboration. This will be in addition to the NHS Trust's existing shareholdings in Sensyne Health. The NHS Long Term Plan identifies cardiovascular disease as a clinical priority and the leading condition where lives can be saved by the NHS over the next 10 years.